Who are GSK Malaria vaccine 257049's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RZV, Zoster Vaccine Recombinant, Adjuvanted, MVC-COV1901(3 Months), RSV prefusion F protein-based vaccine, RSVpreF 120 µg, MVC-COV1901(6 Months).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk-malaria-vaccine-257049.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

GSK Malaria vaccine 257049 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK Malaria vaccine 257049 (GSK Malaria vaccine 257049) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Subunit vaccine. Area: Infectious Disease.

phase 2 Subunit vaccine Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

GSK Malaria vaccine 257049 (GSK Malaria vaccine 257049) — GlaxoSmithKline. Induces immune response against Plasmodium falciparum

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GSK Malaria vaccine 257049 TARGET	GSK Malaria vaccine 257049	GlaxoSmithKline	phase 2	Subunit vaccine
RZV	RZV	GlaxoSmithKline	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant, Adjuvanted	Zoster Vaccine Recombinant, Adjuvanted	Wuhan BravoVax Co., Ltd.	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
MVC-COV1901(3 Months)	MVC-COV1901(3 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
RSV prefusion F protein-based vaccine	rsv-prefusion-f-protein-based-vaccine	Pfizer Inc.	marketed	Viral protein subunit vaccine	Respiratory syncytial virus fusion (F) protein
RSVpreF 120 µg	rsvpref-120-g	Pfizer	marketed	Recombinant subunit vaccine	Prefusion form of the RSV F protein
MVC-COV1901(6 Months)	MVC-COV1901(6 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein (S-2P)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Subunit vaccine class)

GlaxoSmithKline · 1 drug in this class
Statens Serum Institut · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK Malaria vaccine 257049 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-malaria-vaccine-257049. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab